Department of Pediatrics, Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis, TN, USA.
Pediatr Crit Care Med. 2013 Jan;14(1):27-36. doi: 10.1097/PCC.0b013e318253c80e.
To examine the clinical factors associated with increased opioid dose among mechanically ventilated children in the pediatric intensive care unit.
Prospective, observational study with 100% accrual of eligible patients.
Seven pediatric intensive care units from tertiary-care children's hospitals in the Collaborative Pediatric Critical Care Research Network.
Four hundred nineteen children treated with morphine or fentanyl infusions.
None.
Data on opioid use, concomitant therapy, demographic and explanatory variables were collected. Significant variability occurred in clinical practices, with up to 100-fold differences in baseline opioid doses, average daily or total doses, or peak infusion rates. Opioid exposure for 7 or 14 days required doubling of the daily opioid dose in 16% patients (95% confidence interval 12%-19%) and 20% patients (95% confidence interval 16%-24%), respectively. Among patients receiving opioids for longer than 3 days (n = 225), this occurred in 28% (95% confidence interval 22%-33%) and 35% (95% confidence interval 29%-41%) by 7 or 14 days, respectively. Doubling of the opioid dose was more likely to occur following opioid infusions for 7 days or longer (odds ratio 7.9, 95% confidence interval 4.3-14.3; p < 0.001) or co-therapy with midazolam (odds ratio 5.6, 95% confidence interval 2.4-12.9; p < 0.001), and it was less likely to occur if morphine was used as the primary opioid (vs. fentanyl) (odds ratio 0.48, 95% confidence interval 0.25-0.92; p = 0.03), for patients receiving higher initial doses (odds ratio 0.96, 95% confidence interval 0.95-0.98; p < 0.001), or if patients had prior pediatric intensive care unit admissions (odds ratio 0.37, 95% confidence interval 0.15-0.89; p = 0.03).
Mechanically ventilated children require increasing opioid doses, often associated with prolonged opioid exposure or the need for additional sedation. Efforts to reduce prolonged opioid exposure and clinical practice variation may prevent the complications of opioid therapy.
探讨小儿重症监护病房机械通气患儿阿片类药物剂量增加的相关临床因素。
前瞻性观察研究,对符合条件的患者进行 100%入组。
协作儿科危重病研究网络的 3 家三级儿童医院的 7 个小儿重症监护病房。
419 名接受吗啡或芬太尼输注治疗的患儿。
无。
收集阿片类药物使用、伴随治疗、人口统计学和解释变量的数据。临床实践存在显著差异,基础阿片类药物剂量、平均日剂量或总剂量或峰值输注率的差异高达 100 倍。16%(95%置信区间为 12%-19%)和 20%(95%置信区间为 16%-24%)的患者需要将每日阿片类药物剂量增加 1 倍才能达到 7 天或 14 天的阿片类药物暴露量。在接受阿片类药物治疗超过 3 天的患者中(n=225),分别有 28%(95%置信区间为 22%-33%)和 35%(95%置信区间为 29%-41%)的患者在第 7 天和第 14 天达到此剂量。阿片类药物输注 7 天或更长时间(比值比 7.9,95%置信区间为 4.3-14.3;p<0.001)或联合使用咪达唑仑(比值比 5.6,95%置信区间为 2.4-12.9;p<0.001)后,更有可能增加阿片类药物剂量,而如果使用吗啡作为主要阿片类药物(与芬太尼相比)(比值比 0.48,95%置信区间为 0.25-0.92;p=0.03),初始剂量较高(比值比 0.96,95%置信区间为 0.95-0.98;p<0.001),或患者有小儿重症监护病房入院史(比值比 0.37,95%置信区间为 0.15-0.89;p=0.03),则不太可能增加阿片类药物剂量。
机械通气患儿需要增加阿片类药物剂量,这通常与延长阿片类药物暴露时间或需要额外镇静有关。减少长期阿片类药物暴露和临床实践差异的努力可能预防阿片类药物治疗的并发症。